NCT02319824View on ClinicalTrials.gov

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Conditions
Sarcoma
Interventions
BIOLOGICAL

Autologous NY-ESO-1-specific CD8-positive T Lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Palliative Radiation Therapy

Undergo palliative radiation therapy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT02319824 - NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy | Biotech Hunter | Biotech Hunter